Innate Pharma Reports First Quarter 2025 Results

Innate Pharma announces a €15 million investment from Sanofi, strengthening the partnership on the ANKET® program. The first patient has been treated in a Phase 1 trial for IPH4502, targeting Nectin-4, with presentations planned for the AACR and ASCO 2025 meetings. Lacutamab obtains Breakthrough Therapy designation for Sézary syndrome. As of March 31, 2025, cash position is €72.5 million, excluding the Sanofi payment. Financial results show revenue of €1.2 million compared to €6.6 million the previous year. A conference call is planned to discuss these advancements.